Provided herein are compositions and methods for preventing calcification of replacement heart valves. In particular, provided herein are compositions and methods for increasing local production of adenosine on or in the valve.

The present invention is directed to an absorbable hemostatic patch that utilizes a biocompatible fibrous, fabric substrate that is melt-blown and napped or loosened at the surface, with the substrate having a low-profile, high flexibility, strength and porosity that is suitable for coating cross-linkable active molecules and ultimately effective for use as a hemostat in situations of problematic bleeding.

The present disclosure relates to biocompatible injectable compositions. The provided compositions comprise or consist of silk fibroin, hyaluronic acid, horseradish peroxidase, hydrogen peroxide, and water. The injectable composition is tunable and may be adapted to have a gelation time from 3 minutes to 20 minutes, a storage modulus of 6 Pa to 4000 Pa, be injectable through a needle having a size from 32 G to 18 G, have optical transmittance from 75% to 95% for at least one wavelength from 400 nm to 700 nm, have a volume expansion from 5% to 400% relative to an original volume of the hydrogel after soaking in an aqueous solution for 12 hours, and/or have a hydrogel stability by maintaining at least 75% of the storage modulus and the optical transmittance of the hydrogel after 6 months in vivo. The present disclosure provides methods for making and using the same.

Liquid compositions are described which have enzyme that is able to convert a substrate to release hydrogen peroxide; substrate for the enzyme; and polymer. The substrate is less than 10% by weight of the composition and the composition does not comprise sufficient free water to allow the enzyme to convert the substrate, or has a water activity of 0.7 or less.

The present invention relates to a hemostatic composition including collagen, a stabilizer, and thrombin, and a container holding this hemostatic composition. The hemostatic composition and the container holding this hemostatic composition can be applied to an urgent bleeding patient by a simple method of use, and the hemostatic composition is less toxic, does not have a problem of blood infection, has a fast rate of biodegradation, has an excellent hemostatic effect, and can be usefully used as a hemostat.

Provided is a thrombin-carrying hemostatic sheet that is suitable for hemostasis during surgery, in particular, for hemostasis during spine surgery, that is convenient without preparation before use, and that is bioabsorbable and can be embedded in the body as it is. The hemostatic sheet is composed of a gelatin sponge carrying an effective amount of thrombin, wherein (A) the density is 30 to 55 mg/cm.sup.3, and (B) the shape maintaining angle in wet conditions is 55 to 120°.

The present application relates to use of transglutaminases to treat various products, including medical devices such as tissue grafts, tissue matrices or other tissue-derived materials, and synthetics. The transglutaminases can be applied to the medical devices to provide advantages such as adhesion resistance or abrasion resistance.

A mesh-based composition comprising a cross-linkable protein or polypeptide and one or more cross-linking materials according to at least some embodiments. The mesh-based composition may comprise a self-adhering surgical mesh which requires no additional fixation while at the same time minimizes adhesions. The mesh may be in the form of a composite mesh featuring a foamed composition of the cross-linkable protein and a non-toxic material that induces cross-linking of the cross-linkable protein. The composite mesh may be in a sheet-like form.

The present invention is directed to compositions and methods for preventing and/or treating diseases and disorders of patients caused by non-Staphylococcal microorganisms. In particular, compositions and methods contain lysostaphin, altered forms of lysostaphin as compared to wild-type, and synergistic combinations of lysostaphin plus additional conventional treatments such as other enzyme, antibiotic and/or antibody treatment. The invention is also directed to detecting and identifying altered forms of lysostaphin that possess increased efficacy against infections as compared to wild-type lysostaphin, and forms that generate a minimal or no immune response in a patient. The invention is also directed to method of manufacturing lysostaphin and altered forms of lysostaphin, and compositions that direct the lysostaphin to the site of the infection such as aerosolized nanoparticles.

Storage-stable compositions for generating antimicrobial activity are described. The compositions comprise an enzyme that is able to convert a substrate to release hydrogen peroxide, and an unrefined natural substance, such as a honey, that includes a substrate for the enzyme. In certain embodiments, the enzyme is a purified enzyme. In other embodiments, the substrate lacks catalase activity, and the enzyme is additional to any enzyme activity able to convert the substrate to release hydrogen peroxide that may be present in the unrefined natural substance. The storage-stable compositions do not include sufficient free water to allow the enzyme to convert the substrate. Use of the compositions to treat microbial infections and wounds is described, as well as methods for their production.